CAMBRIDGE, Mass., Aug. 26 /PRNewswire/ -- Biogen said today that patents
relating to interferon beta-1a will not expire for a decade. U.S. 5326859
expires in 2011 and U.S. 5514567 expires in 2013.
(Photo: http://www.newscom.com/cgi-bin/prnh/20000502/NETU048 )
Today's The Wall Street Journal incorrectly stated that the patent
expiration date for Avonex(R) was 2003. 2003 is when the seven-year Orphan
Drug exclusivity granted to Avonex upon approval in 1996 is set to expire.
About Biogen
Biogen, Inc., winner of the U.S. National Medal of Technology, is a
biotechnology company principally engaged in discovering and developing drugs
for human healthcare through genetic engineering. Headquartered in Cambridge,
MA, the Company's revenues are generated from U.S. and European sales of
AVONEX(R) (Interferon beta-1a) for treatment of relapsing forms of multiple
sclerosis, (Please see full prescribing information at
http://www.avonex.com.), and from the worldwide sales by licensees of a number
of products, including alpha interferon and hepatitis B vaccines and
diagnostic products.
Biogen's research and development activities are focused on novel products
to treat inflammatory and autoimmune diseases, neurological diseases, cancer,
fibrosis and congestive heart failure. The Company maintains active clinical
research programs in protein therapeutics, small molecules, genomics and gene
therapy. For copies of press releases and additional information about the
Company, please consult Biogen's homepage on the World Wide Web at
http://www.biogen.com.
SOURCE Biogen, Inc.
 back to top
Related links:
http://www.biogen.com
Photo Notes:
NewsCom:
http://www.newscom.com/cgi-bin/prnh/20000502/NETU048
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, 888-776-6555 or 212-782-2840
Company News On-Call:
http://www.prnewswire.com/comp/101550.html
CONTACT:
Tim Hunt, Director, Public Affairs,
+1-617-679-4996; or Elizabeth Woo, Director, Investor Relations,
+1-617-679-2822, both of Biogen
|
